PET Coverage-With-Evidence Debate Continues: AHIP Urges Restraint
This article was originally published in The Gray Sheet
Executive Summary
Private insurers say data collected in a registry of Medicare cancer patients that have undergone positron emission tomography imaging does not support broader coverage of FDG-PET oncology applications
You may also be interested in...
PET Scan Registry Reports Two-Year Results; Medicare Policy Still Pending
Researchers hope that updated data from the National Oncologic PET Registry will influence CMS to change its coverage policy for positron emission tomography scans in cancer
PET Scan Registry Reports Two-Year Results; Medicare Policy Still Pending
Researchers hope that updated data from the National Oncologic PET Registry will influence CMS to change its coverage policy for positron emission tomography scans in cancer
MedCAC Says PET Data Is Too Weak To Remove Registry Requirement
CMS should maintain its data collection requirements for coverage of positron emission tomography for nine cancers, because the evidence linking PET to improved outcomes is still weak, the Medicare Evidence Development and Coverage Advisory Committee concluded at its Aug. 20 meeting